SEARCH RESULTS

Dr Shailesh Ayyangar conferred Officer of the National Order of Merit

Julian HOARAU - 17-nov.-2016 06:04:04
Mumbai, 15 November 2016 On behalf of the President of the French Republic, H.E. Mr Alexandre Ziegler, Ambassador of France to India, conferred the high French distinction, Officier de l’Ordre national du Mérite (Officer of the National Order of Merit) on Dr. Shailesh Ayyangar, Managing Director - India and Vice President - South Asia, Sanofi, on Tuesday, 15th November 2016. The honour comes in recognition of his outstanding contribution and dedication to promoting public health, particularly amongst children and diabetics, and turning scientific innovations into therapeutic solutions. Dr Shailesh Ayyangar Dr Shailesh Ayyangar , born on 15th October 1954, is the Managing Director - India and Vice President - South Asia, Sanofi (Global healthcare leader present in India since 1956) and President - Organisation of Pharmaceutical Producers of India (OPPI), unanimously elected for four consecutive years since 2013. A graduate in Veterinary Science, Dr Ayyangar holds a Post-graduate Degree in Business Management from the Indian Institute of Management (IIM), Ahmedabad, Gujarat. In his career spanning over three decades, he has gathered wide-ranging experience in the pharmaceutical industry. In April 2002 he joined Sanofi as Managing Director, which was further extended to the combined Company Sanofi-Aventis, in 2005. In 2010, he was assigned additional responsibilities for Sanofi’s South Asia Zone comprising Pakistan, Bangladesh, India, Nepal and Sri Lanka. In 2014, Dr Ayyangar was listed among ‘India’s Best CEOs’ in Mid-Sized Companies category by Business India magazine, and in 2013, he was recognized as ‘Most Valuable CEO’ in Mid-Sized Companies category by Business World magazine. Along with his corporate vision for positioning Sanofi as a market leader, Dr Ayyangar also undertook initiatives for social and educational development. Thus, Sanofi India has implemented several projects for promoting public health, particularly amongst children and diabetics. Sanofi provides full financing for a programme – supported by the Public Health Foundation of India – aimed at promoting hygiene among Indian schoolchildren. Further, Sanofi India helps towards recreational facilities in Indian hospitals and conducts free health check-ups near its Goa plant. At Dr Ayyangar’s initiative, almost 300 Sanofi employees carry out voluntary work for the benefit of underprivileged children in Mumbai. It may be noted that the company also came to the aid of people severely affected by the 2013 and 2014 floods in North India. Ordre National du Mérite Ordre National du Mérite  (French National Order of Merit) was instituted in 1963 by General Charles de Gaulle. It is awarded for distinguished services rendered in public, civil, military posts, or a private profession.

Indian government assures full support to French companies to invest in India

Thomas ILHE - 11-févr.-2015 08:41:50
The government has assured full support to address the challenges of French companies wanting to invest and manufacture in India. Addressing a seminar organised by The Indo-French Chamber of Commerce and Industry ( IFCCI), Secretary in the Department of Industrial Policy and Promotion (DIPP) Amitabh Kant said that the government is working alongside companies to ensure that there is an ease in doing business in India. The DIPP assured it will "extend all possible support to address the challenges of French companies wanting to invest and manufacture in India," Kant said. France is one of the top foreign investors in India. India has received $ 4.4 billion FDI from the European nation during April 2000 and November 2014. Firms that participated in the event include Airbus Group, Danone Nutricia, Safran India, Sanofi India, Schneider Electric India and Renault India. The discussions mainly revolved around French companies that are already making in India, their India strategy, growth stories, and challenges and how they foresee India as a potential manufacturing hub.  Currently, 950 French companies (350 firms, 400 subsidiaries and 200 entrepreneurs) are established in India. These companies employ more than 3,00,000 skilled staff in India. Source: PTI

Shantha Bio receives WHO nod for Pentavalent Vaccine

Anindita BANERJEE - 14-mai-2014 13:46:31
Shantha Biotechnics, a Sanofi group company, today said its paediatric pentavalent vaccine Shan5, developed and manufactured indigenously, has received prequalification status from the World Health Organisation (WHO). The status qualifies Shan5 vaccine for purchase by United Nations agencies, mainly UNICEF, said Harish Iyer, Shantha CEO in a media briefing here. "Shan5 prequalification will give more children around the world access to the latest high-quality, fully-liquid, 5-in-1 vaccine and help secure the supply of pentavalent combination vaccines in over 50 emerging and low-income countries," Iyer said. Pentavalent vaccine provides effective protection for children from 6 weeks of age against five diseases: diphtheria, tetanus, pertussis, Hib and hepatitis B. Replying to query, he said Sanofi has invested over Rs 1,000 crore in Shantha since its acquisition in 2009. He said the demand for the vaccine is around 200 million vials and the company is expecting to garner good chunk of market share in future. An earlier version developed by the vaccine maker was recognised by WHO and the company sold 18 million doses between 2008 and 2010. However, it was later withdrawn due to some issues in the sedimentation of the vaccine. Varaprasad Reddy, founder of Shantha Biotechnics and Non-Executive Chairman of the board said they are committed and focused to the priority and passion which is to serve people through high quality, affordable vaccines. Source : PTI

Sanofi India appoints N Rajaram as Country Head

Nathalie OSTERNAUD - 22-avr.-2014 09:04:41
Mumbai, April 15 Sanofi India Ltd, a global healthcare leader, today announced the appointment of N Rajaram as its Country Head and General Manager- Pharmaceutical Operations, India with effect from April 2014. Rajaram reports to Shailesh Ayyangar, Vice President- South Asia, Sanofi and Managing Director- Sanofi India Ltd, a statement issued here said. Rajaram joins Sanofi India with over two decades of experience in FMCG industry with Hindustan Unilever, and in the telecom industry with Airtel. He will be responsible for driving the company’s ambitious growth plans in the pharmaceutical and consumer healthcare segments. "The healthcare industry in India is on the threshold of major transformation- as we address the problem of increasing access to quality healthcare and medicines to our large population. Rajaram’s vast experience and consumer insights will help drive Sanofi’s growth strategy in India," Ayyangar said. Source : PTI

Sanofi files cases against Glenmark on patent infringement

Nathalie OSTERNAUD - 12-mars-2014 07:22:18
Hyderabad, March 5th,  French drug-maker Sanofi filed patent infringement petition against Glenmark on cardiac drug Multaq, in the district court of Delaware, on three counts. According to the petition, the Indian drug maker had submitted its application to seek US Food and Drug Administration’s (USFDA’s) approval for its generic version of the drug on January 24, 2014. Sanofi and Sanofi-Aventis US LLC filed the suit against Glenmark and Dublin-based Actavis (Watson) on February 26, 2014 in the US court seeking to prevent the duo from commercialising its ANDA product prior to the expiration of certain US patents. The lawsuit was filed under the provisions of the Hatch- Waxman Act, resulting in a stay on final FDA approval of Actavis’ ANDA until Jan 1, 2017, or final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Multaq, is an anti-arrhythmic drug indicated to reduce the risk of hospitalisation for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF. For the 12 months ending December 31, 2013, Multaq had total US sales of approximately USD 319 million, according to IMS Health data. Actavis is most likely to get the 180 days exclusivity of the drug. However, based on the outcome of the court and FDA approval, if Glenmark negotiates successfully they may get shared exclusivity, Dalal said. A first-to-file status on generic application allows the generic drug firm 180 days of marketing exclusivity after the innovator patent expiry. Source PTI
About
Sophie Clavelier, Country Head   Welcome to the French Trade Commission Business France in India!     Our key mission is to promote trade relations between France and India. We assist French- based companies seeking potential partners and new markets in India, while helping Indian businesses to identify potential French suppliers, commercial and technical partners.   In India, our 4 offices are located in business hubs, New Delhi, Mumbai, Bengaluru and Chennai. We have a dedicated multicultural team of 38 experts in the following growing sectors: Agrofood Industry Industry and Cleantech Lifestyle and Healthcare Tech & Services Our Trade Commission also has a Press office in charge of helping French companies to communicate in India as well as a Market Access Department enabling them to better understand and adjust to the Indian regulatory and fiscal framework. In

READ MORE

Facebook
Press area & Media Gallery
List of last comments

Bluestorage is a subsidiary of the Bollo...

Malcolm MESSIER | février 22, 2019

AdBGQi Thank you for this impressive rep...

best pron | janvier 29, 2018

pYktcT Well I definitely liked studying ...

just another | novembre 08, 2017

dv1KAR Say, you got a nice post.Thanks A...

best pron | septembre 20, 2017